{ "docId": "019de516-01ce-701d-bd9b-acac15fa9fab", "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88", "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides", "authorId": "oculis", "authorName": "Oculis", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "pageCount": 39, "prevPage": 35, "nextPage": 37, "slideType": "timeline", "function": "plan_implementation", "density": "overcrowded", "nDataPoints": 1, "notes": null, "elementsJson": null, "metadataConfidence": 0.9, "imagePath": null, "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/36", "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab", "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json", "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-36", "components": [ { "bbox": { "h": 0.13, "w": 0.04, "x": 0.03, "y": 0.29 }, "kind": "legend", "text": "Business Milestones", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "52f8cbb8-e2f6-4d37-863c-09ebe86dbf91", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.13, "w": 0.04, "x": 0.03, "y": 0.69 }, "kind": "legend", "text": "Financial highlights", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ab5dfa0b-f07c-43bd-b1be-3221bb9b40db", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.38, "x": 0.09, "y": 0.63 }, "kind": "list", "text": "> USD 110 m private funding from leading international life sciences investors", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0b2edd0b-f533-45df-9fbd-f738161df541", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.4, "x": 0.51, "y": 0.69 }, "kind": "list", "text": "Adequately capitalized with cash runway into 2026", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4e009d39-6200-481a-822c-edd7098248ac", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.11, "x": 0.55, "y": 0.83 }, "kind": "list", "text": "1 NDA application", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "5789fc65-371f-42f5-bcb4-3e6961109074", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.11, "x": 0.55, "y": 0.8 }, "kind": "list", "text": "6 clinical readouts", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6902d580-c603-446e-9cf8-dee4aa119a5b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.38, "x": 0.09, "y": 0.73 }, "kind": "list", "text": "Strong and balanced portfolio: OCS-01, OCS-02 and OCS-05", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "75e4db4c-32d4-4250-a833-3c68a44988bb", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.12, "x": 0.57, "y": 0.31 }, "kind": "list", "text": "✓ OCS-01 DME Ph3 Stage 1\nOCS-01 Oc Sx Ph3", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "9a232f8d-5e43-4ee3-9753-382ec611a46b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.51, "y": 0.63 }, "kind": "list", "text": "Successful Merger with EBAC and listing on Nasdaq: March 3, 2023", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ab043659-50e3-4cad-bacb-632e2d1936d5", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.38, "x": 0.09, "y": 0.69 }, "kind": "list", "text": "Successful clinical validation of OPTIREACH® / OCS-01", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "cec44a69-755e-4dbd-8fec-e06c84a0ced3", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.51, "y": 0.73 }, "kind": "list", "text": "Track record of success and well funded to deliver key business milestones in 2023 and 2024:", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d3f505f5-797e-4468-b32a-65c2c1358282", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.38, "x": 0.09, "y": 0.77 }, "kind": "list", "text": "Efficient deployment of of capital transforming Oculis into multiple assets with late-stage candidates", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ed97332c-756b-47fe-a7dd-1466dfcfb559", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.14, "x": 0.71, "y": 0.31 }, "kind": "list", "text": "OCS-02 DED Ph 2b\nOCS-02 Uveitis Ph 2b\nOCS-05 AON Ph 2 PoC\nOCS-01 CME Ph 2 PoC\nOCS-01 Oc Sx NDA", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "eee5d733-9ccf-46a5-9d59-c4bd1d7d46ce", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.07, "w": 0.2, "x": 0.26, "y": 0.39 }, "kind": "list", "text": "OCS-02 Biologic eye drop: Novartis in-licensing Technical development advancement", "attrs": null, "subkind": "timeline-item", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "48179c12-3d7a-4f9c-9d17-3ccc547fb4f5", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.16, "x": 0.09, "y": 0.29 }, "kind": "list", "text": "OCS-01 Optireach® animal & human PoC", "attrs": null, "subkind": "timeline-item", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "49d74448-b389-447e-b915-f0f711f216dc", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.11, "w": 0.2, "x": 0.26, "y": 0.25 }, "kind": "list", "text": "OCS-01 Optireach® clinical validation in DME/retina and Oc Sx Positive EoP2 with FDA for DME and Ocular Sx commenced Phase 3 studies", "attrs": null, "subkind": "timeline-item", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "be74a9ec-6638-481b-bb63-95334a8d3917", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.07, "w": 0.12, "x": 0.47, "y": 0.36 }, "kind": "list", "text": "OCS-05 Neuroprotective disease modifying technology in-licensing", "attrs": null, "subkind": "timeline-item", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e4db1b4b-f5a4-4ec7-8d5b-a6fbbabaf965", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.09, "x": 0.87, "y": 0.33 }, "kind": "other", "text": "Building a world leader in ophthalmology", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "80dfd928-8a53-4f17-b319-7e2b0be21682", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.57, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Track Record of Efficient Capital Deployment", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b7b1a249-107a-4729-9164-3d70684553e8", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 39, "from": 25, "beatId": "6cce666b-f795-4a3e-a589-afe2a7266ece", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 25-39 discuss OCS-02, OCS-05, and the track record of efficient capital deployment.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }